SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17 at 07:27 AM688506-2.93%02615
Mobile’s Cash Flow Surges 128% as Gome Resorts to Share Issuance for Debt SurvivalGlobal Report·Jul 7 at 05:38 AM00951-2.17%00788-0.20%
15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in Chinaprnewswire·Jun 22 at 02:09 PM688506-2.93%02615
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancerbiopharmadive·Feb 26 at 07:55 PM688506-2.93%02615
Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%Wallstreetcn·Dec 7, 2025 at 04:48 AM02615688506-2.93%
【New Stock Listing】BIOKIN (2615) subscription entry fee is 39,293 yuan, and 5 funds including the US-listed pharmaceutical company BMS are invested in the stocketnet·Nov 6, 2025 at 05:59 PM02615
